Polymyositis without Beneficial Response to Steroid Therapy:Should Miyoshi Myopathy be a Differential Diagnosis? by Scalco, Renata Siciliani et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
 10.12659/AJCR.900970
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Scalco, R. S., Lorenzoni, P. J., Lynch, D. S., Martins, W. A., Jungbluth, H., Quinlivan, R., ... Houlden, H. (2017).
Polymyositis without Beneficial Response to Steroid Therapy: Should Miyoshi Myopathy be a Differential
Diagnosis?. American Journal of Case Reports, 18, 17-21.  10.12659/AJCR.900970
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Received: 2016.08.09
Accepted: 2016.10.12
Published: 2017.01.05
 1236   1   1   18
Polymyositis without Beneficial Response 
to Steroid Therapy: Should Miyoshi Myopathy 
be a Differential Diagnosis?
 ABDEF 1,2,3 Renata Siciliani Scalco*
 EF 4 Paulo José Lorenzoni*
 ACD 1 David S. Lynch
 BE 2 William Alves Martins
 DE 5,6,7 Heinz Jungbluth
 DE 1 Ros Quinlivan
 ABD 2 Jefferson Becker
 ACD 1 Henry Houlden
  * Both authors contributed equally to this publication
 Corresponding Author: Henry Houlden, e-mail: h.houlden@ucl.ac.uk
 Conflict of interest: None declared
 Patient: Male, 16
 Final Diagnosis: Miyoshi myopathy
 Symptoms: HyperCKemia • myalgia • weakness
 Medication: —
 Clinical Procedure: —
 Specialty: Neurology
 Objective: Rare disease
 Background: Miyoshi myopathy (MM) is an autosomal-recessive muscle disorder caused by mutations in the DYSF gene. 
Clinical features and histopathological changes in dysferlinopathies may mimic inflammatory myopathies and 
a high degree of clinical suspicion is required to guide the genetic investigation.
 Case Report: We report the case of a 16-year-old male who presented with severe bilateral calf pain and elevated CK lev-
els (15 000 IU/l) who was on prolonged steroid therapy prompted by the clinical suspicion of inflammatory 
myopathy. Three years into his illness, he was referred for neuromuscular evaluation presenting with untreat-
able muscle pain and progressive weakness. The diagnosis of “refractory polymyositis” was revisited. Targeted 
exome sequencing revealed homozygous pathogenic mutations in the DYSF gene, confirming a diagnosis of 
Miyoshi myopathy.
 Conclusions: Our case illustrates that severe muscle pain may be the initial feature of Miyoshi myopathy and should be con-
sidered in the differential diagnosis of inflammatory myopathies. Although the described patient reported partial 
clinical improvement in muscle pain, steroid treatment is not an effective therapy for dysferlinopathy patients 
and it did not prevent disease progression. In addition, we confirm the utility of next-generation sequencing 
approaches to myopathies, particularly in complex or unusual cases when muscle biopsy is not available.
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Background
Miyoshi myopathy (MM) is an autosomal-recessive muscle dis-
order caused by mutations in the DYSF gene (OMIM #603009) 
characterized by an early adult onset muscular dystrophy pre-
dominantly characterized by distal and posterior leg muscle 
involvement in association with markedly elevated serum cre-
atine kinase (CK) levels [1–3]. The diagnosis is confirmed by 
reduced dysferlin protein expression in muscle biopsy and/or 
confirmed pathogenic mutations in the DYSF gene [1,4]. We 
report a patient who presented with severe muscle pain in as-
sociation with elevated CK levels who was initially misdiag-
nosed as having polymyositis.
Case Report
A Brazilian teenage boy reported severe myalgia affecting calf 
muscles at the age of 16. He was initially diagnosed with an in-
flammatory myopathy (polymyositis). Steroid treatment (pred-
nisone 80mg/day) was prescribed, with a partial clinical im-
provement of the myalgia. Unfortunately, muscle biopsy, muscle 
MRI, and genetic tests were not available when he was first 
treated. Past medical history had been uneventful. Attempts to 
reduce the steroid dose resulted in worsening of muscle pain, 
which became increasingly severe and limited his physical ac-
tivities. He was also hampered by adverse effects, including 
cushingoid-appearance and weight gain. As the disease pro-
gressed, he reported difficulty climbing stairs and frequent 
falls while walking long distances. Fatigue was prompted by 
moderate exertion. As muscle weakness and pain progressed, 
he was referred to neuromuscular evaluation. A physical exam 
performed 3 years following the clinical onset revealed sym-
metrical weakness in the arms (MRC 4+ proximally and MCR 
4 distally) and in the legs (MRC 4 proximally and MRC 3 distal-
ly). Distal weakness was evident in lower limbs with weakness 
of both feet, particularly in foot flexion (MRC 3) with associ-
ated inability to walk on the toes. Muscle atrophy was promi-
nent in the calves (Figure 1A). There was no facial weakness or 
scapular winging. There were no cardiorespiratory symptoms. 
Further investigation revealed elevated serum CK levels (>15 
000 IU/L; normal range: 60–174 IU/L). Needle electromyogra-
phy showed myopathic features (lower limbs > upper limbs). 
Lower limbs muscle MRI performed at a later stage showed bi-
lateral involvement of the posterior compartment (Figure 1B).
His parents were first-degree cousins. His father died at age 
50 years due to an unexplained cardiac arrhythmia. His moth-
er did not report neuromuscular symptoms apart from gener-
alized fatigue. His 3 sisters were asymptomatic.
Even though this patient was initially diagnosed as having in-
flammatory myopathy, the clinical phenotype was very atypical 
for polymyositis and was more consistent with an underlying 
neuromuscular disorder such as MM. His parents were first-
degree cousins, which increased the suspicion of an inherited 
disease. To confirm the existence of an underlying neuromus-
cular disorder, targeted exome sequencing (Illumina Trusight) 
was performed and revealed a homozygous frameshift dele-
tion of ‘TC’ at position c.3149_3150del (p. Leu1050Glnfs*63) 
in exon 29 of the DYSF gene (Figure 1C) and a heterozygous 
V62l variant in the MYF6 gene (herculin). Sanger sequenc-
ing confirmed that both variants were also present in the pa-
tient’s mother in the heterozygous state. Following the ge-
netic diagnosis, the patient’s mother underwent a physical 
exam and had normal results, with normal electromyography 
results and a slightly increased CK measurement (268 IU/L; 
VR: 30–135 IU/L). Steroid therapy was discontinued and ami-
triptyline was prescribed for muscle pain, with mild improve-
ment of the muscle pain.
Discussion
Clinical features and histopathological changes in dysferlinopa-
thies may mimic inflammatory myopathies, and a high degree 
of clinical suspicion is required to guide the genetic investiga-
tion [5]. Physical examination is likely to reveal predominance 
of distal weakness and muscle atrophy mainly affecting poste-
rior segments of the legs, with inability to stand on the toes, 
which is an important diagnostic clue for MM [2,6–8].
Approximately 25% of patients with DYSF gene mutations are 
initially misdiagnosed as having polymyositis [2] and approxi-
mately 10% to 15% of patients with MM may have received the 
clinical diagnosis of an inflammatory myopathy before immu-
nohistochemical analysis for dysferlin became available [2,5]. 
Misdiagnosis of MM as inflammatory myopathy has been pre-
viously reported in 8 cases (Table 1) [2,5,7,9,10] although this 
could be an underestimate. Misdiagnosis often concerned spo-
radic forms of the disease not responsive to steroid treatment, 
based on clinical assessment and/or histopathological evalua-
tion [5,7,9]. The correct diagnosis of MM diagnosis was even-
tually established by dysferlin immunostaining on muscle bi-
opsy and/or genetic analysis in the described cases.
Muscle biopsy in dysferlinopathies may show inflammato-
ry infiltration [5–7,9], further leading to a misdiagnosis of in-
flammatory myopathy [4,7,9] highlighting the importance of 
performing dysferlin immunostaining when assessing mus-
cle biopsies of young adults presenting with muscle pain and 
other non-specific features, in whom inflammatory myopa-
thy was initially suspected [5,7,9]. The widespread upregulat-
ed MHC-I expression in muscle fibers can also help in the his-
tological differentiation of these disorders because it is more 
evident in polymyositis [11], although different patterns of 
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upregulation have been reported in association with dysfer-
linopathies [2,4,12,13]. Partial invasion has been described in 
association with myositis [11]. The presence of inflammatory 
infiltrates in muscle biopsy of dysferlinopathies has been as-
sociated with a higher rate of disease progression [2].
The reported patient was initially misdiagnosed with an inflam-
matory myopathy prompted by severe muscle pain and high 
CK levels. Unfortunately, muscle biopsy, muscle MRI, and ge-
netic investigation were not performed at an early stage due 
to public health system limitations [14,15], which, in associa-
tion with the partial improvement of the myalgia in response 
to steroid treatment, contributed to the delay in considering 
a genetic cause. Although the described patient reported par-
tial clinical improvement in muscle pain [7], steroid treatment 
is not an effective therapy for dysferlinopathy patients and 
it did not prevent muscle weakness and disease progression 
[6,9,16]. We suggest that patients presenting with muscle pain 
initially diagnosed with polymyositis “refractory” to treatment 
should undergo muscle biopsy at an early stage or genetic in-
vestigation for an underlying neuromuscular disorder such as 
dysferlinopathy, especially if muscle pathology immunostain-
ings are restricted and miss important staining such as dys-
ferlin immunostaining, even if more typical features of these 
conditions have not evolved yet.
The frameshift deletion in the DYSF gene found in our pa-
tient was previously reported as pathogenic, causing limb-gir-
dle muscular dystrophy type 2B in another Brazilian patient 
(see Leiden DYSF mutation database, unpublished case) [17]. 
A C
B
Figure 1.  Clinical, radiological, and genetic features in the reported case. Illustration of the leg muscle atrophy (A). Lower-limb muscle 
MRI showed bilateral muscle atrophy mainly affecting the posterior compartment, increased signal in T1-weighted image 
representing fat infiltration, and fibrosis in the calf regions (B). Chromatogram demonstrated the result of DYSF gene 
sequencing in the patient and his unaffected mother (C).
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Variants in the MYF6 gene have been reported as a genetic 
modifier in X-linked muscular dystrophy [18]; however, with-
out additional functional data it is very difficult to prove that 
the MYF6 V62I variant identified acted as a genetic modifier 
in our patient. The patient’s mother carried the same MYF6 
V62I variant and was asymptomatic apart from a very mildly 
raised CK level (268 IU/L; VR: 30–135 IU/L).
Conclusions
We reported a patient with MM who initially presented with 
severe muscle pain misdiagnosed as polymyositis resistant to 
steroid therapy. Myalgia partially improved with steroid treat-
ment even though distal muscle weakness slowly progressed. 
This case illustrates that diagnosis and treatment based sole-
ly on clinical presentation may not be an appropriate method 
Case
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Present 
case
Sex M M M F NI NI M M M
Age at onset (years) 17 17 17 26 NI NI 21 20 16
Age (years)** NI NI 45 30 NI NI 22 50 19
Family history – – + – NI – – – –
CK* >10(?) >10(?) 38 36 NI >10(?) 41 8 86
Neurophysiology NI NI Myop Myop NI NI Myop Myop Myop
PM diagnosis by C MBwd MBwd MBwd MBwd NI MBwd MBwd C
Muscle biopsy:
  Inflammatory 
infiltrate
– + + + + + + + NK
 Dysferlin deficiency +WB +WB NK NK +IH +IH/WB +IH +IH NK
Genetic analysis*** NK NK + + +(?) +(?) – – +
PM therapy CC CC CC CC CC CC CC, IVIg CC, IVIg CC
Beneficial PM therapy – – –# –# – NI – – –#
Table 1. Previously published patients in the English literature with Miyoshi myopathy misdiagnosed as polymyositis.
MM – Miyoshi myopathy; PM – polymyositis; CK – serum creatine kinase level; * times above normal value; ** age at MM diagnosis; 
*** pathogenic mutations in the DYSF gene; ‘+’ – present or positive; ‘–’ – absent or negative; ‘±’ – reduced; C – clinical data; 
MBwd – muscle biopsy without dysferlin analysis; Myop – myopathic changes; IH – immunohistochemistry; WB – western blot; 
CC – corticosteroid; IVIg – intravenous immunoglobulin; NK – not performed; NI – no information; # showed transient responses at the 
initial treatment; (?) – no full information in the article.
because different conditions may overlap in the early mani-
festation. Polymyositis usually responds dramatically to ste-
roid therapy, either histologically or clinically. In the absence of 
such a dramatic response, more diagnostic attempts, includ-
ing either dysferlin immunostaining or Western blot analysis, 
should be undertaken. Our observation confirms that next-
generation sequencing approaches, through disease-specific 
panels or targeted exome sequencing, are very helpful in the 
evaluation of the differential diagnosis of inherited neuromus-
cular disorders, especially when muscle biopsy is not available, 
as occurred in our case.
Acknowledgment
The authors would like to thank The MRC, Wellcome Trust 
and NIHR BRC.
References:
 1. Kawabe K, Goto K, Nishino I et al: Dysferlin mutation analysis in a group 
of Italian patients with limb-girdle muscular dystrophy and Miyoshi myop-
athy. Eur J Neurol, 2004; 11: 657–61
 2. Nguyen K, Bassez G, Krahn M et al: Phenotypic study in 40 patients with 
dysferlin gene mutations: High frequency of atypical phenotypes. Archi 
Neurol, 2007; 64: 1176–82
 3. Udd B: Distal myopathies – New genetic entities expand diagnostic chal-
lenge. Neuromuscul Disord, 2012; 22: 5–12
20
Scalco R.S. et al.: 
Misdiagnosis in Miyoshi myopathy
© Am J Case Rep, 2017; 18: 17-21
This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
 4. Angelini C, Grisold W, Nigro V: Diagnosis by protein analysis of dysferlinop-
athy in two patients mistaken as polymyositis. Acta Myol, 2011; 30: 185–87
 5. Park HJ, Hong JM, Suh GI et al: Heterogeneous characteristics of Korean 
patients with dysferlinopathy. J Korean Med Sci, 2012; 27: 423–29
 6. Austin SG, Pappolla MA, Dimachkie M, Vriesendorp FJ: A confusing case of 
Miyoshi distal myopathy. Muscle Nerve, 1995; 18: 922–23
 7. Cho HJ, Sung DH, Kim EJ et al: Clinical and genetic analysis of Korean pa-
tients with Miyoshi myopathy: identification of three novel mutations in 
the DYSF gene. J Korean Med Sci, 2006; 21: 724–27
 8. Soares CN, de Freitas MR, Nascimento OJ et al: Myopathy of distal lower 
limbs: the clinical variant of Miyoshi. Arq Neuropsiquiatr, 2003; 61: 946–49
 9. Gallardo E, Rojas-Garcia R, de Luna N et al: Inflammation in dysferlin my-
opathy: Immunohistochemical characterization of 13 patients. Neurology, 
2001; 57: 2136–18
 10. Park YE, Kim HS, Lee CH et al: Two common mutations (p.Gln832X and 
c.663+1G>C) account for about a third of the DYSF mutations in Korean 
patients with dysferlinopathy. Neuromuscul Disord, 2012; 22: 505–10
 11. Hilton-Jones D: Myositis mimics: how to recognize them. Curr Opin 
Rheumatol, 2014; 26: 663–70
 12. Jethwa H, Jacques TS, Gunny R, Wedderburn LR et al: Limb girdle muscular 
dystrophy type 2B masquerading as inflammatory myopathy: Case report. 
Pediatr Rheumatol Online J, 2013; 11: 19
 13. Cenacchi G, Fanin M, De Giorgi LB, Angelini C: Ultrastructural changes in dys-
ferlinopathy support defective membrane repair mechanism. J Clin Pathol, 
2005; 58: 190–95
 14. Zavascki AP: Brazil’s Family Health Strategy. N Engl J Med, 2015; 373: 
1277–78
 15. Trevisol DJ, Traebert J, Schuelter-Trevisol FL: Brazil’s Family Health Strategy. 
N Engl J Med, 2015; 373: 1277
 16. Walter MC, Reilich P, Thiele S et al: Treatment of dysferlinopathy with de-
flazacort: A double-blind, placebo-controlled clinical trial. Orphanet J Rare 
Dis, 2013; 8: 26
 17. Dysferlin. Available from: http://www.dmd.nl/nmdb/variants.php?select_
db=DYSF&action=view&view=0002535%2C0000541%2C0 [cited 2015 15 
May 2015]
 18. Kerst B, Mennerich D, Schuelke M et al: Heterozygous myogenic factor 6 
mutation associated with myopathy and severe course of Becker muscu-
lar dystrophy. Neuromuscul Disord, 2000; 10: 572–77
21
Scalco R.S. et al.: 
Misdiagnosis in Miyoshi myopathy
© Am J Case Rep, 2017; 18: 17-21
This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
